13
1
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T6216 | Abiraterone | CB-7598 | P450 |
Abiraterone (CB-7598) (CB-7598) is an effective steroidal cytochrome P450 17alpha-hydroxylase-17, 20-lyase (CYP17) inhibitor (IC50: 4 nM). | |||
T6032 | Birabresib | OTX-015,OTX015 (MK 8628/Birabresib),MK-8628 | Epigenetic Reader Domain |
Birabresib (MK-8628) is a synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential antineoplastic activity. | |||
T6215 | Abiraterone Acetate | Zytiga,CB7630 | P450 |
Abiraterone Acetate (CB7630) is an androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER. | |||
T74684 | Abiraterone sulfate | ||
Abiraterone sulfate is a metabolite of Abiraterone . Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity [1] . | |||
TP2379 | Ebiratide | Ebiratida,Ebiratidum | |
Ebiratide is an analog of ACTH 4-9. | |||
T74094 | 5,6-Dihydroabiraterone | ||
5,6-Dihydroabiraterone, a metabolic derivative of Abiraterone, is a potent and irreversible inhibitor of CYP17A1, exhibiting antiandrogen and antitumor activities, particularly effective against castration-resistant pros... | |||
T83214 | Abiraterone sulfate N-oxide | ||
Abiraterone sulfate N-oxide, a carboxylic acid and major metabolite of Abiraterone, is utilized in prostate cancer research [1] [2]. | |||
T74685 | Abiraterone N-oxide | ||
Abiraterone N-oxide is a metabolite of Abiraterone . Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity [1] . | |||
T63434 | Abiraterone decanoate | ||
Abiraterone decanoate is a prodrug of Abiraterone that provides controlled release and long-lasting CYP17 inhibition of Abiraterone using intramuscular (IM) delivery. | |||
T13525 | Abiraterone metabolite 1 | 3β-OH-5α-Abi | Others |
Abiraterone Metabolite 1, a 5β-reduced derivative of abiraterone, acts by inhibiting CYP17A1, thereby blocking androgen synthesis and extending survival in prostate cancer patients. | |||
T76786 | Cabiralizumab | ||
Cabiralizumab (FPA 008), an anti-CSF1R monoclonal antibody (MAb), promotes T cell infiltration and boosts antitumor immune responses. It also prevents osteoclast activation, thereby inhibiting bone destruction, and is ut... | |||
T69963 | Birabresib dihydrate | ||
Birabresib dihydrate was initially developed by Mitsubishi Tanabe Pharma Corporation, but then was licensed by OncoEthix, privately held biotechnology company. OTX015 is a selective bromodomains: BRD2, BRD3, and BRD4 inh... | |||
T10946 | D4-abiraterone | Abiraterone D4A metabolite,CB-7627,Δ4-Abiraterone | Androgen Receptor |
D4-Abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid 5a-reductase (SRD5A), the main metabolite of abiraterone. D4-Abiraterone is also an antagonist of androgen receptor. |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-03650 | BirA Protein, E. coli, Recombinant (His & MBP) | E. coli | E. coli |
The enzyme BirA is a key reagent because of its ability to biotinylate proteins at a specific residue in a recognition sequence. This enzyme is used to biotinylate the C termini of membrane proteins, allowing these prote... |